Patent for artificial pancreas developer:
This article was originally published in Clinica
Ixion Biotechnology has received a US patent covering a technique for growing insulin-producing islet cells in vivo as a long-term treatment for type I diabetes. The Alachua, Florida-based company, which earlier this year became the first US biotechnology firm to launch a public offering on the Internet, is also developing tests and treatments for cystic fibrosis, renal failure, Crohn's disease and other disorders.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.